



BioOutsource Global Expansion

Plans to open a U.S. Lab Facility in Massachusetts in 2015

GLASGOW, Scotland and BOSTON, Mass. – June 25, 2014 – [BioOutsource](#) Ltd. (“BioOutsource”), a global leader in biologics contract testing and BioSimilar characterization for the biopharmaceutical industry, today announced that the last 12 months have been an exceptional growth year for the company. Global demand for outsourced testing services, coupled with BioOutsource’s continued investment in R&D and the opening of a state of the art BioSimilar Centre of Excellence in Glasgow in February 2014, has driven continued development of the company and created the need to establish a new North American Testing Facility in 2015.

BioOutsource revenues have grown by more than 40% over the last 12 months with positive growth delivered across all business units. The company continues to strengthen and reinforce its position as market leader in the biological analysis of BioSimilar molecules.

BioOutsource CEO, Gerry MacKay commented “This year has been an exceptional year for BioOutsource, as we continue to grow and win more market share. Our biggest growth market has without doubt been North America, where we have seen sales triple in the past year.”

Following the successful opening of a US office in 2013, based in the BioTechnology Hub of Cambridge, MA, the company plans to open a Laboratory Facility in the Massachusetts area in early 2015 to service their North American & Latin American clients. The new Laboratory Facility will support and strengthen the company’s BioSimilar and BioSafety service offering.

“North America has always been an essential strategic element of our global expansion plans, exemplified by our US office and active membership of MassBio. We are already a global company and the time is right to extend our global client footprint with the addition of a new facility in the US. The new facility will benefit our existing and new clients, improving logistics and ensuring our technical experts are close by.”

Robert K. Coughlin, President & CEO of MassBio commented “We are excited to welcome Gerry and his team to Massachusetts, as the gateway into business in the U.S.”

Ahead of today’s announcement, CEO, Gerry MacKay met with the Governor of Massachusetts, Deval Patrick and other officials and leaders from Massachusetts at BIO in San Diego. Governor Patrick commented “We welcome BioOutsource’s expansion in Massachusetts and look forward to their ongoing contributions to our thriving life sciences community”.

“We are delighted to announce our plans to open a new Laboratory Facility in the US and a further announcement will be made soon.” concluded Mr. MacKay.



Caption: Left to Right - MassBio President & CEO Robert Coughlin, Massachusetts Senate President Therese Murray, BioOutsource CEO Gerry McKay, Governor Deval Patrick, and Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, Ph.D. celebrate BioOutsource's decision to expand in Massachusetts at the BIO Convention in San Diego.

About BioOutsource Ltd

BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of Biologics, Vaccines & BioSimilar throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry's increasingly preferred testing partner. We understand the importance of our service to support our client's critical testing requirements and as a result, continually strive to provide a world class service globally.

Contacts

For BioOutsource:

Gemma Fulton
Sales & Marketing Associate
BioOutsource Ltd.
gfulton@biooutsource.com
+44 (0)141 426 4222

Verna McErlane
Director of Business Development – Americas & Asia Pacific
BioOutsource Ltd.
vmcerlane@biooutsource.com
+44 (0)141 426 4222